BCMA/CD3 bispecific antibody (CM336)
IIT2025065
Phase 2 small_molecule active
Quick answer
BCMA/CD3 bispecific antibody (CM336) for Solitary Bone Plasmacytoma is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Solitary Bone Plasmacytoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active